T&R Biofab
티앤알바이오팹 · 246710
Health Care Pharmaceuticals · KOSDAQ
Market cap US$71.8M (₩99.1B)
Overview
T&R Biofab makes three-dimensional bioprinting systems and the materials that go with them, including bioink, a gel-like substance that keeps living cells alive during printing, to produce biodegradable scaffolds that help the body regenerate tissue.
Its products serve the regenerative medicine field, and it also supplies surgical products that apply the same biomaterial know-how to a range of surgical procedures. Listed on KOSDAQ, Korea's tech and small-cap board, the company runs three business lines, regenerative medicine, bio-surgical solutions, and cosmetics, with the cosmetics segment added as a nearer-term revenue source while longer-horizon programs such as organoids and cell therapies remain in development.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$3.8M
- FY2024US$3.5M
- FY2025US$19.5M
Operating profit
- FY2023−US$9.2M
- FY2024−US$9.6M
- FY2025−US$6.6M
Net income
- FY2023−US$9.7M
- FY2024−US$5.6M
- FY2025−US$25.3M
Key ratios (FY2025)
Price charts coming soon
Interactive price history isn't here yet. Would you use it?